139886-03-6

Basic information

• Product Name: (E)-N-methoxy-1-(1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)
• CAS NO: 139886-03-6
• Molecular Formula: C₇H₁₂N₂O*ClH
• Molecular Weight: 176.6439
• Mol File: 139886-03-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 220.3°C at 760 mmHg
• Flash Point: 87.1°C
• Vapor Pressure: 0.114mmHg at 25°C
• CAS DataBase Reference: (E)-N-methoxy-1-(1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N-methoxy-1-(1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)(139886-03-6)
• EPA Substance Registry System: (E)-N-methoxy-1-(1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)(139886-03-6)

Safety Data

• Hazardous Substances Data: 139886-03-6(Hazardous Substances Data)

Usage

General Description

(E)-N-methoxy-1-(1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1) is a chemical compound that consists of one molecule of the base compound (E)-N-methoxy-1-(1,2,5,6-tetrahydropyridin-3-yl)methanimine and one molecule of hydrochloride. It is commonly used in pharmaceutical research as a potential drug candidate due to its reported pharmacological activities, such as antipsychotic, anxiolytic, and anti-inflammatory properties. (E)-N-methoxy-1-(1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1) also has potential applications in the field of medicinal chemistry for the development of new drugs for neurological and psychiatric disorders. Additionally, it may be used as a substrate for chemical synthesis in organic chemistry reactions. The hydrochloride salt form of this compound increases its solubility in water, making it more suitable for certain applications in the pharmaceutical and chemical industries.

Upstream product

• 139886-42-3 1-Benzyl-1,2,5,6-tetrahydro-pyridine-3-carbaldehyde O-methyl-oxime 
• 139886-30-9 1-ethyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-methyloxime 
• 139886-32-1 milameline 
• 114485-63-1 5-(Methoxyimino-methyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid 1-chloro-ethyl ester 
• 114485-53-9 3-methoxyiminomethyl-1-ethylpyridinium iodide 
• 57980-43-5 3-Pyridinecarbaldehyde oxime O-methyl ether 
• 593-56-6 N-methoxylamine hydrochloride 
• 114485-48-2 1,2,5,6-tetrahydropyridine-3-carboxaldehyde hydrochloride 

Downstream Products

• 139886-32-1 milameline 
• 139886-42-3 1-Benzyl-1,2,5,6-tetrahydro-pyridine-3-carbaldehyde O-methyl-oxime 

Relevant articles and documents

1-Alkyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyl-oximes: A new class of potent orally active muscarinic agonists related to arecoline

On the basis of the knowledge acquired for basic studies of several known arecoline derivatives about the structural requirements for potent agonistic activity and oral efficacy, a series of 1-alkyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyl-oximes was synthesized and biologically evaluated in a battery of in vitro and in vivo assays. The most interesting molecules to emerge from the primary screening, 1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-methyloxime hydrochloride (11, RU 35963), 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxyaldehyde-O-methyloxime hydrochloride (12, RU 35926), and 1,2,5,6-tetrahydropyridine-3-carboxyaldehyde-O-propargyloxime hydrochloride (30, RU 47029) and 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-propargyloxime hydrochloride (33, RU 35986), were evaluated more extensively, and their cholinomimetic profile was compared with that of the parent molecule, arecoline. The pharmacological results after oral administration to mice and rats revealed that their efficacy is 2-3 orders of magnitude higher than that of arecoline, and, in addition, they show a longer duration of action. The 4 aldoximes showed anti-amnesic properties in many respects superior to those of arecoline. Their anti-amnesic doses were 2 orders of magnitude lower than those inducing obvious cholinergic symptoms, and 3-5 orders of magnitude lower than the lethal doses. These new compounds can be regarded as potential candidates for clinical studies in AD (Alzheimer's disease) patients.